(S)-3-((S)-2-Acetylamino-3-methyl-butyrylamino)-N-{(S)-1-[(2S,3S)-2-((S)-2-hydroxy-5-oxo-tetrahydro-furan-3-ylcarbamoyl)-3-isopropoxy-pyrrolidine-1-carbonyl]-2-methylpropyl}-succinamic acid

ID: ALA1835212

PubChem CID: 56683064

Max Phase: Preclinical

Molecular Formula: C28H45N5O11

Molecular Weight: 627.69

Molecule Type: Small molecule

This compound is available for customization.

Associated Items:

Bioactivity Summary Target Summary Assay Summary

Names and Identifiers

Canonical SMILES: CC(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N1CC[C@H](OC(C)C)[C@H]1C(=O)N[C@H]1CC(=O)OC1O)C(C)C)C(C)C

Standard InChI: InChI=1S/C28H45N5O11/c1-12(2)21(29-15(7)34)25(39)30-16(10-19(35)36)24(38)32-22(13(3)4)27(41)33-9-8-18(43-14(5)6)23(33)26(40)31-17-11-20(37)44-28(17)42/h12-14,16-18,21-23,28,42H,8-11H2,1-7H3,(H,29,34)(H,30,39)(H,31,40)(H,32,38)(H,35,36)/t16-,17-,18-,21-,22-,23-,28?/m0/s1

Standard InChI Key: SARFORDDPYMXPD-VUACEQFZSA-N

Molfile:

     RDKit          2D

 44 45  0  0  0  0  0  0  0  0999 V2000
   14.9308   -5.8292    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.2571   -6.3054    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.5013   -7.0943    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   15.3274   -7.1083    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.5917   -6.3255    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.8051   -7.7808    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   13.4797   -6.0420    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   14.9468   -5.0046    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.1944   -4.6607    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.5335   -3.3480    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.1989   -3.8357    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.8695   -3.3551    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.6175   -2.5669    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.7933   -2.5663    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3915   -3.3480    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1032   -2.9355    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.6756   -2.9355    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3915   -4.1730    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.8190   -3.3480    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5349   -2.9355    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.8190   -4.1730    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1032   -4.5855    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5349   -4.5855    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.2466   -3.3480    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.5349   -2.1105    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.9625   -2.9355    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.6783   -3.3480    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.9625   -2.1105    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.6783   -4.1730    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   10.6783   -1.6980    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.3950   -2.1116    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   10.6791   -0.8741    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   11.3900   -2.9355    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   12.1059   -3.3480    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.8176   -2.9355    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.1059   -4.1730    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.3900   -4.5855    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.8176   -4.5855    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.8176   -2.1105    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   13.4991   -5.1048    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   15.6509   -3.6093    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   16.3566   -3.1819    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.3393   -2.3571    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.0795   -3.5794    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
 14 10  1  0
 11  9  1  1
  1  5  1  0
  4  6  2  0
  2  7  1  0
  1  8  1  1
  9  8  1  0
 10 11  1  0
  1  2  1  0
  2  3  1  0
 15 16  1  0
 15 17  1  0
 15 18  2  0
 16 19  1  0
 19 20  1  0
 19 21  1  6
 21 22  1  0
 21 23  1  0
 20 24  1  0
 20 25  2  0
 24 26  1  0
 26 27  1  0
 26 28  1  1
 27 29  2  0
 28 30  1  0
 30 31  1  0
 30 32  2  0
 27 33  1  0
 33 34  1  0
 34 35  1  0
 34 36  1  6
 36 37  1  0
 36 38  1  0
 35 10  1  0
 35 39  2  0
  3  4  1  0
  9 40  2  0
  4  5  1  0
 12 41  1  6
 11 12  1  0
 41 42  1  0
 12 13  1  0
 42 43  1  0
 13 14  1  0
 42 44  1  0
M  END

Associated Targets(Human)

CASP2 Tchem Caspase-2 (173 Activities)

Discover Target: CASP2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CASP3 Tchem Caspase-3 (3632 Activities)

Discover Target: CASP3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Natural Product: No	Oral: No	Chemical Probe: No	Parenteral: No
Molecule Type: Small molecule	Topical: No	First In Class: No	Black Box: No
Chirality: No	Availability: No	Prodrug: No

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 627.69	Molecular Weight (Monoisotopic): 627.3116	AlogP: -1.61	#Rotatable Bonds: 14
Polar Surface Area: 229.77	Molecular Species: ACID	HBA: 10	HBD: 6
#RO5 Violations: 2	HBA (Lipinski): 16	HBD (Lipinski): 6	#RO5 Violations (Lipinski): 3
CX Acidic pKa: 4.26	CX Basic pKa: ┄	CX LogP: -1.89	CX LogD: -4.89
Aromatic Rings: ┄	Heavy Atoms: 44	QED Weighted: 0.12	Np Likeness Score: 0.41

References

1. Maillard MC, Brookfield FA, Courtney SM, Eustache FM, Gemkow MJ, Handel RK, Johnson LC, Johnson PD, Kerry MA, Krieger F, Meniconi M, Muñoz-Sanjuán I, Palfrey JJ, Park H, Schaertl S, Taylor MG, Weddell D, Dominguez C.. (2011) Exploiting differences in caspase-2 and -3 S₂ subsites for selectivity: structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors., 19 (19): [PMID:21903398] [10.1016/j.bmc.2011.08.020]
2. Chen, Yi-Hua YH and 9 more authors. 2006-03-09 Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. [PMID:16509578]
3. Maillard, Michel C MC and 17 more authors. 2011-10-01 Exploiting differences in caspase-2 and -3 S₂ subsites for selectivity: structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors. [PMID:21903398]

(S)-3-((S)-2-Acetylamino-3-methyl-butyrylamino)-N-{(S)-1-[(2S,3S)-2-((S)-2-hydroxy-5-oxo-tetrahydro-furan-3-ylcarbamoyl)-3-isopropoxy-pyrrolidine-1-carbonyl]-2-methylpropyl}-succinamic acid

Names and Identifiers

Alternative Forms

Associated Targets(Human)

Molecule Features

Drug Indications

Mechanisms of Action

Biocomponents

Calculated Properties

References

Source